2022년 신약개발 정부 R&D 투자 포트폴리오 분석

Summary

Developing new drugs is a lengthy, high-risk process involving various diseases and drug types, necessitating strategic and efficient investment. This report analyzes the South Korean government's R&D investment portfolio in new drug development for 2022, categorized by development stage, drug type, and target disease, to enhance strategy and efficiency. The analysis of past investment trends and portfolio distribution is completed and expected to inform future R&D planning.

Key Facts

Source Document

https://example-government.gov/policy-document-link